newsfilter
← Latest News
GlobeNewswire·

Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

  • Retension Pharmaceuticals (NASDAQ: RTSN) will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, Massachusetts.
  • The event is scheduled for Tuesday, November 10, 2026, at 7:30 a.m. ET.
  • A live webcast of the fireside chat will be available on the Investor Relations section of the company website.
  • Retension is a clinical-stage biopharmaceutical company focused on medicines for hypertension & other cardiovascular diseases.
  • The company's lead candidate, RTN-001, is a next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries.
  • RTN-001 is under development for patients with uncontrolled & resistant hypertension & is being developed under an exclusive worldwide license from Sanofi S.A.
  • Clinical studies of RTN-001 have included 265 enrolled subjects across multiple trials.
  • Two Phase 2 pilot trials demonstrated clinically meaningful placebo-adjusted reductions in systolic & diastolic blood pressure.
  • A Phase 2b trial of RTN-001 for hypertension is currently ongoing.